ArticleAlzheimer's & dementia (New York, N. Y.)2021
The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.
Article in Alzheimer's & dementia (New York, N. Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Association of cognitive impairment and APOE ε4 with Centiloids in Hispanic and non-Hispanic White cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Pooled it
- Developing an SNR-efficient tensor-valued diffusion encoding protocol for studying brain microstructural changes in neurodegeneration.medRxiv : the preprint server for health sciences · 2026Article
- Surgery Is Not Associated With Early Presentation of Alzheimer's Disease and Mild Cognitive Impairment or Increased Risk for Both.CNS neuroscience & therapeutics · 2026Article
- Encoding Discordance in the Alzheimer's Disease A/T/N Framework.medRxiv : the preprint server for health sciences · 2026Article
- Centralized Review of Alzheimer's Disease and Related Dementias Biomedical Repositories and Computational Methods.Bioengineering (Basel, Switzerland) · 2026Review
- Advancing brain health and dementia research in Canada: insights from focus groups with the Dementia Research and Innovation Funders Alliance.The Gerontologist · 2026Article
- Omics-based Cancer Prognosis Across Ethnic Groups: From Feature Engineering to Disparity Detection and Mitigation.IEEE transactions on artificial intelligence · 2026Article
- Cognitive dispersion profiles and prediction of cognitive change in early-onset dementias: Results from LEADS.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Baseline FDG-PET Brain hypometabolism as a predictive biomarker of cognitive decline and Alzheimer's disease risk.The journal of nutrition, health & aging · 2026Article
- Sensitivity comparison of longitudinal cognitive function indicators of Alzheimer's disease after mild cognitive impairment: a prospective cohort study.Scientific reports · 2026Article
- Associations between ventricular boundary shift integral and composite cognitive domains across the alzheimer's disease continuum.Scientific reports · 2026Article
- Late-onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi-center prospective longitudinal observational study (ELUCID).Epilepsia open · 2026Observational
- Advancing global dementia research through equity and inclusion.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Sex differences in cognitive decline and impairment: a scoping review in informatics literature.Biology of sex differences · 2025Article
- Multimodal Self-Supervised Learning for Early Alzheimer's: Cross-Modal MRI-PET, Longitudinal Signals, and Site Invariance.Diagnostics (Basel, Switzerland) · 2025Article
- FDG-PET brain glucose hypometabolism predicts Alzheimer's disease progression pathways in cognitively normal adults: A longitudinal competing risks modeling.Metabolism open · 2025Article
- Decoding the genomic symphony: unravelling brain disorders through data integration and machine learning.Molecular psychiatry · 2025Review
- A digital twin methodology using real patient data for sample size reduction in Alzheimer's disease randomized controlled clinical trials.medRxiv : the preprint server for health sciences · 2025Article
- Clinical Performance of the Elecsys CSF pTauNeurology and therapy · 2025Article
- Comparing the predictive value of plasma p-tau217 and CSF biomarkers (p-tau181, Aβ42) using amyloid positron emission tomography in Alzheimer's continuum.Research square · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 19 institutions in 11 countries.
Funding
Abstract
The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.